Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry
Authors' conclusion
The wrist, MCP2 and MCP3 joints resolve more slowly than other joints following treatment with b/tsDMARDs
Study context
- Population
- Patients with rheumatoid arthritis (RA) from the Swiss Clinical Quality Management in Rheumatic Diseases registry with ≥1 swollen joint at initiation of a b/tsDMARDRA with ≥1 swollen joint
- Participants
- 598 / 242 / 317 / 333 / 176 / 874
- Exposure
- Speed of resolution of individual swollen joints within the 28-joint count vs the wrist
- Tumour necrosis factor inhibitors (TNFi) (bio-naïve)n = 598
- Abataceptn = 242
- IL-6Rin = 317
- Janus kinase inhibitor (JAKi)n = 333
- Rituximabn = 176
- TNFin = 874
- Outcome
- Time to resolution of swollen joints vs wrist
Methodological detailsregistry-based (SCQM), mixed effects models accounting for interval-censored data, 2-year follow-up
- Registry-based (SCQM)
- Mixed effects models accounting for interval-censored data
- 2-year follow-up
Main finding
As reported in the abstract
- Compared with the wrist, all joints demonstrated higher rates of resolution, except for MCP2/3 joints and, in some analyses, the knee
Observational data: associations, not effects.
Further findings
Joint-specific response across all b/tsDMARD classes
- Pattern of joint-specific response consistent across all b/tsDMARDs
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry. RMD Open. Published 23 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →